Tardyferon Fol

Quick links to important sections

Tardyferon Fol

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tardyferon Fol

Property Description
Active Ingredients Ferrous Sulfate and Folic Acid (Vitamin B9)
Form Film-coated prolonged-release tablets
Pharmacological Class Anti-anaemic preparation (Iron and folic acid combination)
Common Use Prevention and treatment of iron and folic acid deficiency
Distinctive Feature Prolonged-release matrix for sustained absorption

Tardyferon Fol is a combination medication containing the essential micronutrients ferrous sulfate and folic acid, specifically formulated to address concurrent deficiencies in the body. The active ingredient, ferrous sulfate, is a readily absorbed iron salt vital for the formation of hemoglobin, which is the protein in red blood cells that transports oxygen throughout the body.

The key differentiating feature of Tardyferon Fol is its prolonged-release tablet formulation. This pharmaceutical technology is designed to control the speed at which the iron component is released into the digestive system. This sustained release helps the body absorb iron more efficiently over time and is engineered to improve the gastrointestinal tolerability often associated with standard oral iron salts.

Folic acid, the second active component, is a B-vitamin necessary for DNA synthesis and the production of healthy red blood cells. As a combined product targeting the development of healthy blood cells, Tardyferon Fol is globally classified as an anti-anaemic preparation.

Regulatory References

  1. NIH: Iron Fact Sheet
  2. WHO Model List of Essential Medicines - Antianaemia

What side effects are possible with Tardyferon Fol?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and regulatory safety characteristics of Tardyferon Fol (Ferrous Sulfate and Folic Acid), based strictly on government-approved prescribing information. This content is non-instructional and focuses on the official classification of reported effects.


Official Adverse Reactions and Frequency

Safety data primarily highlight effects within the Gastrointestinal System as the most frequently reported. These frequencies are based on regulatory classifications:

  • Common Reactions (affecting up to 1 in 10 people): Constipation, Diarrhea, Abdominal distension, Abdominal pain, and Nausea.
  • Uncommon Reactions (affecting up to 1 in 100 people): Dyspepsia (indigestion), Vomiting, Gastritis. Skin reactions such as Pruritus (itching) and Erythema (redness of the skin) are also classified as uncommon.
  • Frequency Not Known: Severe reactions including Anaphylactic shock and Gastrointestinal tract ulceration are listed, but their incidence cannot be accurately estimated from available data.

Documented Safety Considerations

Official labeling groups adverse effects primarily into Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Immune System Disorders. A non-serious, expected effect of oral iron is Faecal discoloration (black stools).

Population-Specific Warnings: Regulatory documents identify older adults and individuals with swallowing difficulties as having a heightened risk of localized injury, such as Oesophageal ulceration or bronchial necrosis, if the prolonged-release tablet is retained in the esophagus or respiratory tract.

Safety Restrictions: The medicine is not indicated for use in individuals with conditions of iron overload (e.g., Haemochromatosis) or in patients with non-iron deficiency anaemias. The folic acid component also introduces a constraint against its use in untreated Vitamin B12 deficiency, as it may mask the underlying neurological progression of the deficiency.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Tardyferon Fol is defined by the severe toxicity potential of the ferrous sulfate component. Overdose manifestations typically begin with gastrointestinal symptoms such as nausea, bloody vomiting, severe abdominal pain, and diarrhea. This may be followed by systemic signs like lethargy and confusion.


Documented Severe Outcomes and Emergency Actions

Regulatory documents specify that overdose can rapidly progress beyond initial distress to life-threatening systemic effects. Severe outcomes include circulatory collapse, shock, hypotension, convulsions, and coma. Long-term complications such as acute hepatic necrosis (liver damage) and gastrointestinal obstruction are also documented.

Immediate medical attention is required upon any suspected overdose. The official regulatory stance emphasizes that accidental ingestion of iron products is a leading cause of fatal poisoning in children under six years old, making the risk in the pediatric population particularly dangerous. Therefore, users must seek immediate medical attention or contact emergency services without delay.

Management procedures described in labeling include the use of the specific antidote Deferoxamine (Desferrioxamine) and the necessary monitoring of serum iron levels during hospitalization.

Therapeutic Uses of Tardyferon Fol

What Tardyferon Fol Treats: Main Uses and Benefits

Tardyferon Fol is commonly used in situations involving certain distressing symptoms linked to iron and folic acid deficiency, offering targeted support when reserves of these vital micronutrients are low. This combination is recognized for addressing such deficiencies and supporting health needs during specific physiological states.


Managing Symptoms Related to Systemic Imbalance

This domain covers the management of symptoms arising from low iron, often referred to as anemia, which cause systemic imbalance. Tardyferon Fol is relevant for easing symptom clusters that create noticeable physiological strain, such as fatigue, pallor, and general weakness. This supportive therapy contributes to easing the overall symptom load, which may help patients cope more steadily with symptom fluctuations.

Relevant in Contexts Involving Heightened Systemic Burden

Tardyferon Fol is commonly applied in clinical settings that involve heightened systemic burden, such as during pregnancy and in certain non-pregnant individuals with confirmed deficiencies. This is relevant when short-term symptomatic assistance is needed to support the demands of the body. The medicine may assist with maintaining functional stability and contributes to improved comfort during periods of increased physiological stress.

Relief for Symptoms that interfere with daily functioning

Regulatory References

  1. World Health Organization (WHO) guidance on antenatal iron supplementation

Eligibility and Restrictions for Use

Official Eligibility Profile

This medicine is designed for individuals diagnosed with iron and/or folic acid deficiency, or those at high risk of deficiency. The official regulatory documents define clear populations for whom use is allowed and for whom it is strictly prohibited (contraindicated).

Who May Use Tardyferon Fol?

Use is allowed for the treatment or prevention of iron and folic acid deficiencies, particularly in two key physiological states:

  • Pregnant Women: Explicitly documented for use during pregnancy for prophylaxis and treatment.
  • Breastfeeding Women: Allowed for use during the breastfeeding period.

Who Must NOT Use Tardyferon Fol (Contraindications)?

Use is strictly prohibited in the following groups to prevent serious complications, primarily related to iron toxicity:

  • Individuals with a known hypersensitivity or allergy to ferrous sulfate, folic acid, or any excipient in the tablet.
  • Patients with iron overload, such as hemochromatosis or hemosiderosis.
  • Patients with anemia not caused by iron deficiency, including aplastic anemia, thalassaemia, or refractory anemia, where iron levels are already normal or high.

Special Considerations:

Special care and professional assessment are required for elderly patients and individuals with swallowing difficulties due to the risk of esophageal ulceration or inhalation of the tablet.

What should I know about interactions with other medicines?

Oral iron supplements, such as the iron component in Tardyferon Fol, can interact with numerous other medicines and supplements, primarily by forming complexes (chelation) that reduce the absorption and effectiveness of both products. To manage this effect, strict spacing is required between administrations.

Combinations Requiring Time Separation

Interacting Product Category Example Medicines Required Spacing (Interval)
Oral Anti-Infectives Cyclines (Tetracyclines), Fluoroquinolones 2 hours or more separation, where possible
Hormone Preparations Thyroid hormones (e.g., Levothyroxine) 2 hours or more separation, where possible
Gastrointestinal Drugs Antacids (Magnesium, Aluminium, Calcium salts) 2 hours or more separation, where possible
Osteoporosis Drugs Oral Bisphosphonates At least 30 minutes to more than 2 hours, where possible
Other Agents Penicillamine, Levodopa, Methyldopa, Entacapone 2 hours or more separation, where possible

Other Significant Interactions

Other supplements containing mineral ions, such as Calcium, Zinc, or Strontium, may also reduce the absorption of the iron component in Tardyferon Fol and should not be taken simultaneously. Additionally, the concurrent use of injectable iron salts is considered an inadvisable combination due to the risk of severe reactions like fainting or shock, which is linked to rapid iron release and the saturation of the protein transferrin. It is important to avoid combining this product with the medicines listed above to ensure therapeutic efficacy.

Mechanism of Action

Iron (Ferrous Sulfate) Mechanism: Heme Synthesis

Ferrous sulfate dissociates in the gastrointestinal tract, allowing the ferrous ion (Fe^2+) to be actively transported across the intestinal brush border membrane by the Divalent Metal Transporter 1 (DMT1). The iron is then transported to the bone marrow where it is incorporated into the protoporphyrin ring to form heme. The absorbed Fe^2+ increases the substrate available for erythropoiesis (red blood cell production) in the bone marrow.

Folic Acid Mechanism: Nucleotide Precursor Synthesis

Folic acid acts as a cofactor in one-carbon metabolism, facilitating the synthesis of purines and pyrimidines (DNA/RNA precursors). Folic acid is reduced to its active form, tetrahydrofolate (THF), by the enzyme dihydrofolate reductase (DHFR). This THF-dependent process is required for the maturation and division of erythroid precursor cells.

Dosage and Administration Information

Tardyferon Fol is administered via the oral route using a prolonged-release film-coated tablet formulation. The product's usage is governed by specific instructions to ensure the correct function of the sustained-release matrix and proper absorption.


Standard Administration Guidelines

Administration Scope Standard Instruction
Route of Administration Oral.
Dosing Schedule One tablet per day (equivalent to 80 mg elemental iron) for adults for both treatment and prevention.
Special Procedural Condition The tablet must be swallowed whole with water; it must not be sucked, chewed, or kept in the mouth.
Timing in relation to meals Taken before or during meals, adjusted according to individual gastrointestinal tolerance.
Missed Dose Rule If a dose is missed, do not take a double dose; the standard regimen should be resumed by taking the next scheduled dose at the usual time.
Use in Pregnancy The typical regimen for pregnant women is one tablet daily or every two days during the second and third trimesters (from the fourth month onward).

Course Duration and Use Protocol

The total duration of use for Tardyferon Fol is generally a long-term course that extends beyond the time required to simply correct the deficiency in the blood. The treatment should be continued until the body's iron stores are fully replenished, which typically requires continuation for three months after normal blood values have been achieved. The requirement to swallow the tablet whole is a necessary procedural step that ensures the integrity of the prolonged-release mechanism, allowing for sustained iron release and absorption over time.

Recent Clinical Evidence

Recent Clinical Evidence for Tardyferon Fol

Tardyferon Fol is a combination product containing ferrous sulfate (an iron salt) and folic acid (vitamin B9), primarily studied for the prevention and management of iron and folic acid deficiencies, especially during pregnancy.


Research Focus: Supplementation in Pregnancy

Clinical trials and systematic reviews have focused on the benefits of daily iron and folic acid supplementation during pregnancy, a period marked by significantly increased demand for both nutrients. The key areas of investigation include:

  • Maternal Outcomes: The use of iron supplementation, often combined with folic acid, has been shown in some studies to reduce the incidence of maternal anemia and improve hematological parameters like hemoglobin and ferritin levels compared to placebo. However, evidence regarding a reduction in maternal mortality remains uncertain.
  • Infant Outcomes: Supplementation during pregnancy is associated with a reduced probability of low infant birthweight compared to no supplementation. Evidence on other adverse birth outcomes, such as preterm birth or neonatal mortality, remains mixed or limited.

Formulation and Pharmacokinetic Studies

Tardyferon Fol is a prolonged-release formulation of ferrous sulfate, which is designed to release iron slowly and evenly over time in the digestive tract. Pharmacokinetic studies on the ferrous sulfate component have confirmed this modified release profile.

Finding Area Clinical Observation / Research Target
Prolonged Release Serum iron concentrations remained elevated for up to 12 hours after a single dose in women with iron deficiency anemia (IDA).
Tolerability The slow, gradual release of iron is theorized to potentially reduce common gastrointestinal side effects (e.g., nausea, constipation) often associated with immediate-release oral iron salts, which can affect patient adherence to therapy.

Frequently Asked Questions (FAQ)

Common questions about Tardyferon Fol (FAQ)


Q: Is Tardyferon Fol a vitamin or an iron supplement?

It is officially classified as an anti-anaemic preparation. It is a combination product that contains two essential micronutrients: ferrous sulfate, which is an iron salt, and folic acid (Vitamin B9). Therefore, it serves as both an iron supplement and a source of the vitamin folic acid.


Q: Does Tardyferon Fol help with anemia not related to pregnancy?

Official information states that the product is indicated for the prevention and treatment of iron and folic acid deficiency. However, regulatory documents also stipulate that its use is strictly prohibited (contraindicated) for anemias that are not caused by iron deficiency, such as thalassaemia. Regulatory documents state that use is determined by the diagnosed deficiency.


Q: Is it normal to have dark stools while taking Tardyferon Fol?

Regulatory safety information indicates that faecal discoloration, commonly presenting as dark or black stools, is an expected physical effect of taking oral iron supplements. This discoloration is tied to the iron content.


Q: Are there any foods or drinks I should avoid while on Tardyferon Fol?

While regulatory documents primarily focus on drug interactions, they recommend taking the supplement before or during meals to help with tolerance. It is known that other mineral ions, such as those found in some calcium or zinc supplements, can reduce iron absorption. Strict spacing from certain products is required to prevent reduced absorption.


Q: Is Tardyferon Fol the same as 'Slow-release Iron'?

Tardyferon Fol is an example of a slow-release iron supplement. Its distinctive feature is a prolonged-release film-coated tablet formulation, which is specifically designed to release the iron component slowly and evenly over time in the digestive tract.


Q: Can men take Tardyferon Fol, or is it only for women?

Tardyferon Fol is allowed for the treatment or prevention of iron and folic acid deficiencies in any individual who has a diagnosed deficiency. Official eligibility is determined by the diagnosed need for the nutrients, regardless of gender, although the product is specifically documented for pregnant and breastfeeding women.


Q: Can Tardyferon Fol cause headaches or dizziness?

Based on the official safety data, headaches and dizziness are not listed among the documented Common or Uncommon Adverse Reactions. This is consistent with the safety profile detailed in regulatory information.


Q: Is it better to take Tardyferon Fol with or without food?

Official administration guidelines state that the tablet should be taken before or during meals. The timing is generally adjusted according to individual gastrointestinal tolerance.


Q: Does Tardyferon Fol require a prescription, or can I buy it over the counter?

The regulatory status of Tardyferon Fol often classifies it as a Medicinal product subject to medical prescription (prescription-only) in many regions. It is not generally available for purchase over the counter.


Q: Are there any long-term risks associated with Tardyferon Fol use?

Regulatory documents carry a strong safety warning against its use in individuals with conditions of iron overload (Haemochromatosis). Because of this risk, regulatory documents emphasize the need for professional assessment before commencing or continuing long-term treatment.


Q: Is Tardyferon Fol more easily absorbed than other types of iron?

Studies on Tardyferon Fol confirm a modified, prolonged-release profile. The sustained-release mechanism is designed to release iron slowly and evenly over time. This approach is theorized to improve the consistency of absorption compared to immediate-release iron salts.


Q: Can Tardyferon Fol cause nausea, and if so, how can it be minimized?

Nausea is listed as a Common Adverse Reaction in the regulatory documents. The prolonged-release formulation is theorized to potentially reduce the severity of gastrointestinal side effects compared to traditional iron salts. Administration guidelines recommend taking the tablet before or during a meal, as this adjustment may help with tolerance.


Q: What is the maximum duration Tardyferon Fol should be taken?

Treatment duration is intended to continue until the body's iron stores are fully replenished. This typically requires continuation for about three months after normal blood values have been achieved. The duration is based on a clinical endpoint rather than a fixed maximum time limit.


Q: Is Tardyferon Fol available in liquid form?

Official product information specifies the formulation as a prolonged-release film-coated tablet administered via the oral route. No liquid formulation is listed as the official presentation.


Q: Does Tardyferon Fol contain any common allergens like gluten or lactose?

Official documentation indicates that the inactive ingredients in the tablet contain lactose monohydrate in some formulations. Individuals with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption are advised in the regulatory documents not to take this medicine.


Q: Can Tardyferon Fol interfere with the absorption of other medications?

Yes, regulatory documents warn that oral iron supplements can interfere with the absorption of numerous other medicines, such as thyroid hormones and certain antibiotics, through chelation. For this reason, strict time spacing between administrations is required with certain medicines.


Q: What is the significance of the 'Fol' part in the drug's name?

The 'Fol' part of the name refers to the secondary active component in the combination product, which is Folic Acid (Vitamin B9). Folic acid is included to support the process of healthy red blood cell formation alongside the iron.


Q: Are there any specific patient groups who should avoid Tardyferon Fol?

Regulatory documents list specific contraindications, which are conditions where use is strictly prohibited. This includes patients with iron overload conditions, those with anemia not caused by iron deficiency, and patients with an untreated Vitamin B12 deficiency.


Q: Is it possible to take too much Tardyferon Fol accidentally?

Official warnings note that accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. For this reason, the product must be stored strictly out of the sight and reach of children.


Q: What is the evidence regarding the absorption rate of Tardyferon Fol?

Pharmacokinetic studies have confirmed the modified release profile of the iron component. The profile was demonstrated in studies where serum iron concentrations remained elevated for up to 12 hours after a single dose.


Q: Does Tardyferon Fol contain vitamin B12?

The active ingredients listed in the official product information are Ferrous Sulfate and Folic Acid (Vitamin B9). Vitamin B12 is not listed as an active component in this specific formulation.


Q: Can I take Tardyferon Fol with my thyroid medication?

Official product information addresses concurrent use with thyroid medication, such as Levothyroxine. A separation of 2 hours or more is required between the two medicines to prevent Tardyferon Fol from reducing the absorption of the thyroid hormone.


Q: Is there a specific time of day that is best to take Tardyferon Fol?

Official administration guidelines recommend taking the tablet before or during a meal, based on individual tolerance. Regulatory documents do not specify a superior time of day (morning or evening). The primary factors in determining timing are consistency and patient tolerance.


Q: Can Tardyferon Fol interact with calcium supplements?

Regulatory documents list supplements containing other mineral ions, such as Calcium, as agents that may reduce the absorption of the iron component. For this reason, they are not intended to be taken simultaneously with Tardyferon Fol.


Q: Why is Tardyferon Fol often prescribed near the beginning of pregnancy?

The typical regimen specified in regulatory documents is for use during the second and third trimesters, starting from approximately the fourth month onward. This timing is specified in regulatory documents to address the increased nutrient demand during those trimesters.


Q: Does taking Tardyferon Fol affect the results of blood tests?

Tardyferon Fol is intended to improve certain blood test results by increasing hematological parameters like hemoglobin and ferritin. Additionally, the folic acid component is noted to potentially mask the neurological progression of an untreated Vitamin B12 deficiency.


Q: Can Tardyferon Fol be taken while breastfeeding?

Official eligibility profiles state that Tardyferon Fol is allowed for use by women during the breastfeeding period for the prevention or treatment of iron and folic acid deficiencies.

How should Tardyferon Fol be stored and disposed of?

How to Store and Dispose of Tardyferon Fol?

Tardyferon Fol must be stored according to regulatory requirements to preserve the stability of the ferrous sulfate and folic acid components.

Storage Requirements

Item Requirement
Temperature Store at a temperature not exceeding 30°C.
Protection Protect from light and store in a dry place.
Container Keep in the original container and keep the container tightly closed.

A critical safety requirement for all iron-containing products is that the medicine must be stored out of the sight and reach of children.

Disposal

Unused or expired Tardyferon Fol must be disposed of following local regulatory requirements and the specific instructions detailed in the official product information. To prevent environmental contamination, the medicine should not be flushed down the toilet or thrown into household waste unless specifically advised by the label or local program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tardyferon Fol found in:

A-Z Index: